1. Home
  2. IHS vs VCEL Comparison

IHS vs VCEL Comparison

Compare IHS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IHS Holding Limited

IHS

IHS Holding Limited

HOLD

Current Price

$8.44

Market Cap

2.8B

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$40.22

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHS
VCEL
Founded
2001
1989
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.4B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
IHS
VCEL
Price
$8.44
$40.22
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$8.29
$57.75
AVG Volume (30 Days)
1.2M
442.3K
Earning Date
05-19-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.00
EPS
N/A
N/A
Revenue
N/A
$276,259,000.00
Revenue This Year
$17.26
$19.40
Revenue Next Year
$7.87
$18.24
P/E Ratio
$5.85
N/A
Revenue Growth
N/A
16.45
52 Week Low
$5.71
$28.95
52 Week High
$8.95
$49.32

Technical Indicators

Market Signals
Indicator
IHS
VCEL
Relative Strength Index (RSI) 54.13 41.83
Support Level $8.11 $35.32
Resistance Level $8.52 $41.25
Average True Range (ATR) 0.04 1.13
MACD -0.01 0.17
Stochastic Oscillator 13.64 57.25

Price Performance

Historical Comparison
IHS
VCEL

About IHS IHS Holding Limited

IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: